Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
67.27
0.2 (0.3%)
Market Cap: 12.82 Bil
Enterprise Value: 12.45 Bil
PE Ratio: 40.28
PB Ratio: 2.37
GF Score: 69/100 
Biomarin Pharmaceutical Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020 / 06:20PM GMT
Release Date Price:
$91.79
(-3.05%)
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Okay. Welcome, everyone. I'm Geoff Meacham. I'm the senior biopharma analyst here at BofA. And welcome to our Virtual Vegas Conference -- Healthcare Conference. We are thrilled this afternoon to have BioMarin. And speaking on behalf of BioMarin we have J.J. Bienaimé, who is Chairman and CEO; and Hank Fuchs, who is President, Worldwide Research & Development. Guys, are you on?
Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development
Yes.
Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO
©,-&
We are.
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Okay. Great. So the format for today is that we'll have some questions with the team here. And of course, there are -- there's technology on the Veracast system to log in and e-mail a
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers